Homo sapiens
Ontology highlight
ABSTRACT:
OTHER RELATED OMICS DATASETS IN: GSE28798
PROVIDER: PRJNA143011 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Expression data from TGF-beta treated Panc-1 pancreatic adenocarcinoma cell line
2025-01-24 | E-GEOD-23952 | ExpressionAtlas
Project description:Expression data from TGF-beta-treated human ovarian fibroblasts
2025-01-24 | E-GEOD-40266 | ExpressionAtlas
Project description:HNF4A-binding sites in HepG2 hepatoblastoma cells treated with TGF-beta
| PRJNA143117 | ENA
Project description:Specific regulation of target genes by transforming growth factor-β (TGF-β) in a given cellular context is determined in part by transcription factors and cofactors that interact with the Smad complex. In the present study, we determined Smad2 and Smad3 (Smad2/3) binding regions in the promoters of known genes in HepG2 hepatoblastoma cells, and compared them to those in HaCaT epidermal keratinocytes to elucidate the mechanisms of cell type- and context-dependent regulation of transcription induced by TGF-β. Our results show that 81% of the Smad2/3 binding regions in HepG2 cells were not shared with those found in HaCaT cells. Hepatocyte nuclear factor 4α (HNF4α) is expressed in HepG2 cells, but not in HaCaT cells, and the HNF4α binding motif was identified as an enriched motif in the HepG2-specific Smad2/3 binding regions. ChIP-sequencing analysis of HNF4A binding regions under TGF-β stimulation revealed that 32.5% of the Smad2/3 binding regions overlapped HNF4A bindings. MIXL1 was identified as a new combinatorial target of HNF4A and Smad2/3, and both the HNF4A protein and its binding motif were required for the induction of MIXL1 by TGF-β in HepG2 cells. These findings generalize the importance of binding of HNF4A on Smad2/3 binding genomic regions for HepG2-specific regulation of transcription by TGF-β, and suggest that certain transcription factors expressed in a cell-type-specific manner play important roles in the transcription regulated by the TGF-β-Smad signaling pathway. HepG2 cells were treated with TGF-beta for 1.5 h or left untreated. anti-HNF4A ChIP-seq was performed. One lane was used for each sample.
2011-06-08 | E-GEOD-28845 | biostudies-arrayexpress
Project description:Expression data from Versican (VCAN) protein treated ovarian cancer cell line OVCA433
2025-01-24 | E-GEOD-40241 | ExpressionAtlas
Project description:Gene expression of hepatocyte cell line (HepG2) treated with H2O2 to induce senescence relative to control untreated cells
2025-01-24 | E-GEOD-47739 | ExpressionAtlas
Project description:RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib
2025-01-23 | E-MTAB-10304 | ExpressionAtlas
Project description:Expression data from NS398-treated and control HT29 colon adenocarcinoma cell line samples
2025-01-24 | E-GEOD-15799 | ExpressionAtlas
Project description:Expression data from MDA-MB-231 cell line treated with Zoledronate, or Fluvastatin, or mock-treated control cells.
2025-01-24 | E-GEOD-33552 | ExpressionAtlas
Project description:RNA-seq of human melanoma cell line A375m2 treated with SB202190 OR BIRB796 against DMSO-treated controls
2025-01-16 | E-MTAB-9273 | ExpressionAtlas